Estrella Immunopharma Inc.
Estrella Immunopharma Inc. (ESLA): 3 pipeline candidates · ~1 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
0.9 months
D/E -1.69
Lead: Phase 1/Phase 2
3 candidates
N/A
N/A
A transparent, data-derived signal for Estrella Immunopharma Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$44.3M
Cash
$1.9M
Quarterly Burn
$6.7M
Runway
0.9 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (3 candidates)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
15
Total value held
$5.9M
| Holder | Shares | Value |
|---|---|---|
| armistice capital, llc | 4,099,000 | $4.3M |
| vanguard capital management llc | 764,938 | $811K |
| wells fargo & company/mn | 264,388 | $280K |
| geode capital management, llc | 157,485 | $167K |
| vanguard fiduciary trust co | 64,921 | $69K |
| renaissance technologies llc | 62,795 | $67K |
| state street corp | 43,252 | $46K |
| blackrock, inc. | 39,890 | $42K |
| northern trust corp | 19,624 | $21K |
| ubs group ag | 15,079 | $16K |
Showing top 10 of 15 institutional holders of Estrella Immunopharma Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Estrella Immunopharma Inc.'s pipeline?
Estrella Immunopharma Inc. (ESLA) has 3 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Estrella Immunopharma Inc.'s lead drug candidate?
Estrella Immunopharma Inc.'s most advanced tracked candidate is eb103 (Phase 1/Phase 2) for B-Cell Non-Hodgkin's Lymphoma (NHL).
What is Estrella Immunopharma Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Estrella Immunopharma Inc. has approximately 0.9 months of cash runway.
What is Estrella Immunopharma Inc.'s market capitalization?
Estrella Immunopharma Inc.'s market capitalization is approximately $44.3M.
Who is the CEO of Estrella Immunopharma Inc.?
Dr. Cheng Liu Ph.D. is the chief executive officer of Estrella Immunopharma Inc. (ESLA).
Get the full picture on Estrella Immunopharma Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.